✦ LIBER ✦

Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation

✍ Scribed by Matthew P. Wright; John D. Shepherd; Michael J. Barnett; Stephen H. Nantel; Heather J. Sutherland; Cynthia L. Toze; Donna E. Hogge; Thomas J. Nevill; Kevin W. Song; Yasser R. Abou Mourad; Sujaatha Narayanan; Maryse M. Power; Clayton A. Smith; Donna L. Forrest

Book ID: 116281238
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 201 KB
Volume: 16
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2009.11.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Decision to Offer Allogeneic Stem Ce

The Decision to Offer Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

✍ Goldman, John M. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 66 KB

Novel tyrosine kinase inhibitor therapy

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia : No evidence for increased transplant-related toxicity

✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI

Allogeneic Hematopoietic Progenitor Cell

Allogeneic Hematopoietic Progenitor Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Lessons Learned to Date

✍ Giralt, Sergio 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 103 KB

Imatinib mesylate is effective in childr

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

✍ Millot, F; Guilhot, J; Nelken, B; Leblanc, T; De Bont, E S; Békassy, A N; Gadner 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 108 KB

248: Novel tyrosine kinase inhibitor the

248: Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity

✍ E. Jabbour; J. Cortes; H. Kantarjian; S. Giralt; R. Champlin; M. de Lima 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Effect of graft sources on allogeneic he

Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis

✍ Ohashi, Kazuteru; Nagamura-Inoue, Tokiko; Nagamura, Fumitaka; Tojo, Arinobu; Miy 📂 Article 📅 2014 🏛 Carden Jennings Publishing 🌐 English ⚖ 795 KB